Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR9 | Q9NR96 | 17/20 | 0.36 |
| ▸ | TLR8 | Q9NR97 | 17/20 | 0.36 |
| ▸ | TLR7 | Q9NYK1 | 17/20 | 0.36 |
| ▸ | ERCC5 | P28715 | 1/20 | 0.35 |
| ▸ | FEN1 | P39748 | 1/20 | 0.35 |
| ▸ | HCAR1 | Q9BXC0 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27377460 | 0.91 | TLR9 (0.35) | TLR9TLR8TLR7ERCC5FEN1 | |
| SCHEMBL29326183 | 0.81 | ERCC5 (0.43) | ERCC5FEN1HCAR1KDM4EALDH1A1 | |
| SCHEMBL29326658 | 0.79 | ERCC5 (0.39) | ERCC5FEN1HCAR1KDM4EALDH1A1 | |
| SCHEMBL29326219 | 0.79 | ERCC5 (0.42) | ERCC5FEN1HCAR1KDM4EALDH1A1 | |
| SCHEMBL29326481 | 0.79 | TLR8 (0.33) | TLR9TLR8TLR7ERCC5FEN1 | |
| SCHEMBL29326194 | 0.78 | ERCC5 (0.40) | ERCC5FEN1HCAR1KDM4EALDH1A1 | |
| SCHEMBL29326196 | 0.76 | CYP1A1 (0.44) | ERCC5FEN1HCAR1KDM4EALDH1A1 | |
| SCHEMBL29326166 | 0.76 | ERCC5 (0.60) | ERCC5FEN1HCAR1KDM4EALDH1A1 | |
| SCHEMBL29326162 | 0.76 | CYP1A1 (0.53) | ERCC5FEN1KDM4EALDH1A1LMNA | |
| SCHEMBL29326188 | 0.76 | CYP1A1 (0.53) | ERCC5FEN1KDM4EALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240239807-A1 | SARS-COV2 MAIN PROTEASE INHIBITORS | GILEAD SCIENCES, INC. | 2024-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240239807-A1 | SARS-COV2 MAIN PROTEASE INHIBITORS | ACE2, TMPRSS2, ACE | TLR9 4729/4885TLR8 4595/4885TLR7 4551/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.